Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Forest Laboratories's Total Stockholders Equity for the quarter that ended in Mar. 2014 was €4,458 Mil. Forest Laboratories's Total Assets for the quarter that ended in Mar. 2014 was €8,689 Mil.
Therefore, Forest Laboratories's Equity to Asset Ratio for the quarter that ended in Mar. 2014 was 0.51.
The historical rank and industry rank for Forest Laboratories's Equity-to-Asset or its related term are showing as below:
FRA:FQX'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51 Med: 0.83 Max: 0.92
Current: 0.51
During the past 13 years, the highest Equity to Asset Ratio of Forest Laboratories was 0.92. The lowest was 0.51. And the median was 0.83.
FRA:FQX's Equity-to-Asset is not ranked
in the Drug Manufacturers industry.
Industry Median: 0.58
vs FRA:FQX: 0.51
Forest Laboratories Equity-to-Asset Historical Data
The historical data trend for Forest Laboratories's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Forest Laboratories's Equity-to-Asset
For the Drug Manufacturers - Specialty & Generic subindustry, Forest Laboratories's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Forest Laboratories's Equity-to-Asset Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Forest Laboratories's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Forest Laboratories's Equity-to-Asset falls into.
Forest Laboratories Equity-to-Asset Calculation
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Forest Laboratories's Equity to Asset Ratio for the fiscal year that ended in Mar. 2014 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Forest Laboratories Equity-to-Asset Related Terms
Thank you for viewing the detailed overview of Forest Laboratories's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.
Forest Laboratories (FRA:FQX) Business Description
Forest Laboratories, Inc. is a Delaware corporation organized in 1956. The Company develops, manufactures and sells branded forms of ethical drug products most of which require a physician's prescription. The Company's most important United States products are marketed directly, or 'detailed,' to physicians by its salesforces. It emphasizes detailing to physicians of those branded ethical drugs which have the most potential for growth and benefit to patients. The Company also develops and introduces new products, including products developed in collaboration with licensing partners. The Company's products include those developed by it and those acquired from other pharmaceutical companies and integrated into its marketing and distribution systems. It actively promotes in the United States those branded products which have the most potential for growth and patient benefit, and which enable its salesforces to concentrate on groups of physicians who are high prescribers of its products. Such products include: Lexapro, its SSRI for the treatment of major depression in adults and adolescents and GAD in adults; Namenda, its NMDA antagonist for the treatment of moderate and severe Alzheimer's disease; Bystolic, its beta-blocker for the treatment of hypertension; and Savella, its newest product, an SNRI for the management of fibromyalgia. The Company's United Kingdom and Ireland subsidiaries sell both ethical products and over-the-counter preparations. Their most important products include Sudocrem, a topical preparation for the treatment of diaper rash; Colomycin, an antibiotic used in the treatment of cystic fibrosis; Infacol, used to treat infant colic; and Exorex, used in the treatment of eczema and psoriasis. The pharmaceutical industry is subject to comprehensive government regulation which substantially increases the difficulty and cost incurred in obtaining the approval to market newly proposed drug products and maintaining the approval to market existing drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:FQX has been successfully added to your 